Notes / Company

Remus Pharmaceuticals Ltd.

REMUS ISIN INE0O5T01011 Trading

Fundamentals

Market cap: ₹935 cr
P/E: 25.29×
ROE: 11.36%
Debt / equity: 0.08
Div yield: 0.12%
52-week range: 580.00 — 1021.80

Research on Tijori Finance

Company snapshot

Remus Pharmaceuticals Ltd.

Miscellaneous

₹702 cr

P/E 24.16×

Latest quarter · Mar 2026

Sales₹453 cr

Net profit₹25 cr

Op. margin+6.6%

EPS₹16.55

Strength & growth

Debt / equity0.08×

Current ratio1.82×

The timeline — 1 note on Remus Pharmaceuticals Ltd.

May 2026

21 May 26 · 3:16 PM IST Brief

Brief · Concalls · Micro cap

Remus Pharma bets on B2C and GLP-1 after 38% revenue jump

FY26 growth was strong, but the real story is the planned shift toward higher-margin consumer revenue, with B2C targeting 30% of sales.

Verify on exchange NSE filings for REMUS Tijori Finance company page